Revisions to the Post-Authorization Activity Table (PAAT) for Giotrif

This PAAT describes post-authorization activity for Giotrif, a product which contains the medicinal ingredient afatinib (as afatinib dimaleate). Based on Health Canada's review, the benefit/risk profile of Giotrif is favourable as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor-naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s). Read more here.